Shattuck Labs secures $54.9M from warrant exercises, extends runway into 2029

What's the deal? Shattuck Labs (STTK) has received notices to exercise roughly 50.6 million warrants, representing 96% of the warrants issued during its August 2025 private placement. The exercises are expected to generate approximately $54.9M in gross proceeds, extending the biotech company's cash runway into 2029.

As of March 31, 2026, Shattuck had already collected $5.6M of that total.

Why now? The near-total exercise rate — 96% — signals strong conviction from investors who participated in the original private placement less than a year ago. Warrant holders typically exercise when they believe the underlying stock is worth more than the exercise price, suggesting confidence in Shattuck's pipeline and trajectory.

What could go wrong? The warrant exercises dilute existing shareholders by adding roughly 50.6 million new shares to the float. For a clinical-stage biotech, a runway extending to 2029 sounds comfortable — but drug development timelines are notoriously unpredictable, and additional capital raises could still be needed if trials expand or stall.

The signal: Warrant exercises are technically dilutive, but a 96% conversion rate from a placement less than a year old is a notable vote of confidence in a clinical-stage biotech. Shattuck Labs, classified as a late-growth-stage company by Dealroom, now has a runway stretching to 2029 — a buffer few small-cap biotechs can claim without tapping public markets again. In a sector where cash shortfalls routinely derail promising pipelines, that financial cushion may matter as much as any trial readout.

Read more: Seeking Alpha

Image: Gel filtration chromatography, MatasNavickas, CC BY-SA 4.0, via Wikimedia Commons.